ACADIA Pharmaceuticals Inc.
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Lewy Body Dementia Psychosis
ACP-204
Placebo
PHASE2
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 180 participants |
Masking : | QUADRUPLE |
Primary Purpose : | TREATMENT |
Official Title : | A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) |
Actual Study Start Date : | 2025-08 |
Estimated Primary Completion Date : | 2028-02 |
Estimated Study Completion Date : | 2028-03 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 55 Years to 84 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
ATP Clinical Research Inc.
Irvine, California, United States, 92612
RECRUITING
Homestead Associates in Research Inc
Miami, Florida, United States, 33032